1d agoThe FlyBULLISH 56Analyst
Archived explainer. For the current picture see today's KYMR page.
Why Is KYMERA THERAPEUTICS (KYMR) Stock Down Today?
By the Top Tier Newswire AI Desk · October 6, 2026 at 10:15 AM ET · reviewed against 3 wire stories
KYMERA THERAPEUTICS (KYMR) is down -6.20% in the latest session. Our newswire has captured 3 stories on KYMR across 2 sources in the last 36 hours, with AI sentiment reading bullish (avg 59/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
KYMR stock is down 6.20% as of the latest trade at $103.04. The decline follows a sharp intraday selloff after the stock opened near $110 and peaked at $111.04. Despite recent positive analyst activity including raised price targets and a bullish outlook on drug development, the stock has struggled to maintain upward momentum. The sell-off may reflect profit-taking or broader market sentiment amid a volatile session.
What Happened
Kymera Therapeutics experienced a significant drop in share price after opening near its 52-week high. The stock reached $111.04 at the session's start but quickly declined to a low of $102.79 by 10:10 AM ET. Citigroup and other analysts have recently raised their price targets for the stock, with Citi setting a new $150 target and maintaining a Buy rating. Stifel and B of A Securities also raised their targets to $152 and $144 respectively. Despite these upgrades, the stock has not been able to sustain its earlier gains.
The company announced the completion of enrollment in its Phase 2b BROADEN2 trial of KT-621 for atopic dermatitis, with topline data expected by year-end 2026 and Phase 3 trials planned for mid-2027. However, the stock's performance today suggests that investors may be reacting to broader market conditions or taking profits after a recent rally.
What The Data Shows
The stock has traded 0.2 million shares so far today, which is 0.2 times its 3-month average daily volume. Over the last 8 trading sessions, the stock has fallen 3.2% from $115.53 to $111.89. On October 6, the stock printed one fresh 52-week high and 16 fresh 52-week lows. Recent insider transactions include two sales totaling $4.2 million, with the most recent being a sale by CEO Nello Mainolfi on October 1.
What To Watch
Investors should monitor the company’s progress in its clinical trials and the release of topline data for KT-621 in late 2026. Analyst coverage and price target adjustments will also remain key factors influencing the stock's direction.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
KYMR by the numbers
Last: $103.04Session: -6.20%7 sessions: -3.15%Coverage: 3 stories / 2 sourcesAI sentiment: 59/100 (bullish)Mkt cap: $8.9B52w: $55.26 to $130.05
The headlines behind the move
1d agoInvesting.com Analyst RatingsBULLISH 61Analyst
Citi raises Kymera Therapeutics stock price target on drug potential
Citi raises Kymera Therapeutics stock price target on drug potential
1d agoThe FlyBULLISH 61Analyst
Kymera Therapeutics price target raised to $150 from $135 at Citi
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on KYMR: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier KYMR move explainers: 2026-10-06